KR100554899B1 - 고체 열성형성 방출 조절 약제 조성물 - Google Patents

고체 열성형성 방출 조절 약제 조성물 Download PDF

Info

Publication number: KR100554899B1
Authority: KR; South Korea
Prior art keywords: pharmaceutical composition; active ingredient; solid; eudragit; controlled release
Prior art date: 1999-06-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

KR1020000035933A

Other languages

English (en)

Korean (ko)

Other versions

KR20010049643A (ko

Inventor

패트릭 우쓰리치

헤르베 롤랜드

질레스 브리아울트

제랄드 피촌

프랑세스 타라울트

Original Assignee

르 라보레또레 쎄르비에르

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-28

Filing date

2000-06-28

Publication date

2006-02-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9547360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100554899(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-28 Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르

2001-06-15 Publication of KR20010049643A publication Critical patent/KR20010049643A/ko

2006-02-24 Application granted granted Critical

2006-02-24 Publication of KR100554899B1 publication Critical patent/KR100554899B1/ko

2020-06-28 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 58
239000007787 solid Substances 0.000 title claims abstract description 39
238000013270 controlled release Methods 0.000 title claims description 27
239000004480 active ingredient Substances 0.000 claims abstract description 101
239000000203 mixture Substances 0.000 claims abstract description 94
229920000193 polymethacrylate Polymers 0.000 claims abstract description 47
238000003856 thermoforming Methods 0.000 claims abstract description 11
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 58
229920003134 Eudragit® polymer Polymers 0.000 claims description 54
238000000034 method Methods 0.000 claims description 42
238000001125 extrusion Methods 0.000 claims description 27
229920000642 polymer Polymers 0.000 claims description 21
238000002347 injection Methods 0.000 claims description 15
239000007924 injection Substances 0.000 claims description 15
239000004014 plasticizer Substances 0.000 claims description 9
CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical group C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
229960001213 benfluorex hydrochloride Drugs 0.000 claims description 6
-1 anti Arrhythmia Substances 0.000 claims description 5
CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical group C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 claims description 4
239000003146 anticoagulant agent Substances 0.000 claims description 4
238000010276 construction Methods 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
229960000764 rilmenidine Drugs 0.000 claims description 4
PICRXJDULXLJCZ-UHFFFAOYSA-N n-[2-(5-ethyl-1-benzothiophen-3-yl)ethyl]acetamide Chemical group CCC1=CC=C2SC=C(CCNC(C)=O)C2=C1 PICRXJDULXLJCZ-UHFFFAOYSA-N 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical group C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 claims description 2
FIKFLLIUPUVONI-UHFFFAOYSA-N 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;hydrochloride Chemical group Cl.O1C(=O)NCC11CCN(CCC=2C=CC=CC=2)CC1 FIKFLLIUPUVONI-UHFFFAOYSA-N 0.000 claims description 2
229930186147 Cephalosporin Natural products 0.000 claims description 2
108050006400 Cyclin Proteins 0.000 claims description 2
102000016736 Cyclin Human genes 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
208000018737 Parkinson disease Diseases 0.000 claims description 2
229930182555 Penicillin Natural products 0.000 claims description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical group C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims description 2
229940035676 analgesics Drugs 0.000 claims description 2
229940035674 anesthetics Drugs 0.000 claims description 2
230000000954 anitussive effect Effects 0.000 claims description 2
239000005557 antagonist Substances 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
239000004004 anti-anginal agent Substances 0.000 claims description 2
230000003474 anti-emetic effect Effects 0.000 claims description 2
229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
230000002460 anti-migrenic effect Effects 0.000 claims description 2
239000000883 anti-obesity agent Substances 0.000 claims description 2
230000000648 anti-parkinson Effects 0.000 claims description 2
230000002921 anti-spasmodic effect Effects 0.000 claims description 2
230000000767 anti-ulcer Effects 0.000 claims description 2
239000000043 antiallergic agent Substances 0.000 claims description 2
229940124345 antianginal agent Drugs 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
229940125681 anticonvulsant agent Drugs 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
229940005513 antidepressants Drugs 0.000 claims description 2
229940125708 antidiabetic agent Drugs 0.000 claims description 2
239000003472 antidiabetic agent Substances 0.000 claims description 2
239000002111 antiemetic agent Substances 0.000 claims description 2
229940121375 antifungal agent Drugs 0.000 claims description 2
239000000739 antihistaminic agent Substances 0.000 claims description 2
229940125715 antihistaminic agent Drugs 0.000 claims description 2
239000003524 antilipemic agent Substances 0.000 claims description 2
239000002246 antineoplastic agent Substances 0.000 claims description 2
229940125710 antiobesity agent Drugs 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
239000000939 antiparkinson agent Substances 0.000 claims description 2
239000000164 antipsychotic agent Substances 0.000 claims description 2
229940005529 antipsychotics Drugs 0.000 claims description 2
239000003434 antitussive agent Substances 0.000 claims description 2
229940124584 antitussives Drugs 0.000 claims description 2
239000003443 antiviral agent Substances 0.000 claims description 2
239000002876 beta blocker Substances 0.000 claims description 2
229940097320 beta blocking agent Drugs 0.000 claims description 2
239000003781 beta lactamase inhibitor Substances 0.000 claims description 2
229940126813 beta-lactamase inhibitor Drugs 0.000 claims description 2
230000036772 blood pressure Effects 0.000 claims description 2
208000006218 bradycardia Diseases 0.000 claims description 2
230000036471 bradycardia Effects 0.000 claims description 2
239000000480 calcium channel blocker Substances 0.000 claims description 2
239000002327 cardiovascular agent Substances 0.000 claims description 2
229940125692 cardiovascular agent Drugs 0.000 claims description 2
229940124587 cephalosporin Drugs 0.000 claims description 2
150000001780 cephalosporins Chemical class 0.000 claims description 2
239000002934 diuretic Substances 0.000 claims description 2
229940030606 diuretics Drugs 0.000 claims description 2
239000002532 enzyme inhibitor Substances 0.000 claims description 2
229960000695 fenspiride hydrochloride Drugs 0.000 claims description 2
239000000796 flavoring agent Substances 0.000 claims description 2
235000019634 flavors Nutrition 0.000 claims description 2
235000003599 food sweetener Nutrition 0.000 claims description 2
239000003193 general anesthetic agent Substances 0.000 claims description 2
229960000346 gliclazide Drugs 0.000 claims description 2
239000003326 hypnotic agent Substances 0.000 claims description 2
230000000147 hypnotic effect Effects 0.000 claims description 2
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical group CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 2
229960004569 indapamide Drugs 0.000 claims description 2
239000003695 memory enhancer Substances 0.000 claims description 2
150000004957 nitroimidazoles Chemical class 0.000 claims description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
229940049954 penicillin Drugs 0.000 claims description 2
239000000813 peptide hormone Substances 0.000 claims description 2
229960004310 piribedil Drugs 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
239000003368 psychostimulant agent Substances 0.000 claims description 2
150000007660 quinolones Chemical class 0.000 claims description 2
239000000932 sedative agent Substances 0.000 claims description 2
229940125723 sedative agent Drugs 0.000 claims description 2
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 2
239000003765 sweetening agent Substances 0.000 claims description 2
230000009885 systemic effect Effects 0.000 claims description 2
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
229940124549 vasodilator Drugs 0.000 claims description 2
239000003071 vasodilator agent Substances 0.000 claims description 2
230000001643 venotonic effect Effects 0.000 claims description 2
FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 claims 1
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical group C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims 1
HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical group C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 claims 1
LIEGBMFMKADERS-FDOHDBATSA-N [(1r)-1-[[2-[[(2r)-2-acetamido-3-phenylpropanoyl]-cyclopentylamino]acetyl]amino]-4-(diaminomethylideneamino)butyl]boronic acid;hydrochloride Chemical group Cl.C([C@@H](NC(=O)C)C(=O)N(CC(=O)N[C@@H](CCCN=C(N)N)B(O)O)C1CCCC1)C1=CC=CC=C1 LIEGBMFMKADERS-FDOHDBATSA-N 0.000 claims 1
230000003288 anthiarrhythmic effect Effects 0.000 claims 1
230000001772 anti-angiogenic effect Effects 0.000 claims 1
230000003262 anti-osteoporosis Effects 0.000 claims 1
230000002785 anti-thrombosis Effects 0.000 claims 1
229960005475 antiinfective agent Drugs 0.000 claims 1
239000004599 antimicrobial Substances 0.000 claims 1
239000002249 anxiolytic agent Substances 0.000 claims 1
230000000949 anxiolytic effect Effects 0.000 claims 1
229940005530 anxiolytics Drugs 0.000 claims 1
229940124630 bronchodilator Drugs 0.000 claims 1
239000000168 bronchodilator agent Substances 0.000 claims 1
239000000812 cholinergic antagonist Substances 0.000 claims 1
239000003086 colorant Substances 0.000 claims 1
230000001506 immunosuppresive effect Effects 0.000 claims 1
239000003223 protective agent Substances 0.000 claims 1
230000003637 steroidlike Effects 0.000 claims 1
229960003352 tertatolol Drugs 0.000 claims 1
229920000307 polymer substrate Polymers 0.000 abstract description 2
238000000338 in vitro Methods 0.000 description 20
238000004090 dissolution Methods 0.000 description 12
239000011159 matrix material Substances 0.000 description 12
239000010410 layer Substances 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000003814 drug Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
239000004148 curcumin Substances 0.000 description 5
238000010828 elution Methods 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 4
229920003149 Eudragit® E 100 Polymers 0.000 description 3
229920002845 Poly(methacrylic acid) Polymers 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 3
230000008859 change Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
238000000465 moulding Methods 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000001192 hot extrusion Methods 0.000 description 2
239000012729 immediate-release (IR) formulation Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
ZPBJVLPCCXWLOF-UHFFFAOYSA-N 1,3-benzothiazole pyridazine Chemical compound N1=NC=CC=C1.S1C=NC2=C1C=CC=C2 ZPBJVLPCCXWLOF-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
SSONCJTVDRSLNK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;hydrochloride Chemical compound Cl.CC(=C)C(O)=O SSONCJTVDRSLNK-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
UPSZHUPTPLMKQT-LREBCSMRSA-N C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.C(C1=CC=CC=C1)(=O)OCCNC(CC1C2=CC=CC=C2C=2C=CC=CC12)=O Chemical compound C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.C(C1=CC=CC=C1)(=O)OCCNC(CC1C2=CC=CC=C2C=2C=CC=CC12)=O UPSZHUPTPLMKQT-LREBCSMRSA-N 0.000 description 1
229920003139 Eudragit® L 100 Polymers 0.000 description 1
229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
229920003141 Eudragit® S 100 Polymers 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 description 1
229960001264 benfluorex Drugs 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000012886 linear function Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
125000005641 methacryl group Chemical group 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229960000347 tertatolol hydrochloride Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

KR1020000035933A 1999-06-28 2000-06-28 고체 열성형성 방출 조절 약제 조성물 Expired - Fee Related KR100554899B1 (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9908210A FR2795326B1 (fr)	1999-06-28	1999-06-28	Composition pharmaceutique solide thermoformable a liberation controlee
FR99.08210		1999-06-28

Publications (2)

Publication Number	Publication Date
KR20010049643A KR20010049643A (ko)	2001-06-15
KR100554899B1 true KR100554899B1 (ko)	2006-02-24

Family

ID=9547360

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020000035933A Expired - Fee Related KR100554899B1 (ko)	1999-06-28	2000-06-28	고체 열성형성 방출 조절 약제 조성물

Country Status (22)

Country	Link
US (1)	US6319520B1 (fr)
EP (1)	EP1064935B2 (fr)
JP (2)	JP2001031591A (fr)
KR (1)	KR100554899B1 (fr)
CN (1)	CN1174744C (fr)
AT (1)	ATE395045T1 (fr)
AU (1)	AU765885B2 (fr)
BR (1)	BR0002880A (fr)
CA (1)	CA2312545C (fr)
CY (1)	CY1110351T1 (fr)
DE (1)	DE60038848D1 (fr)
DK (1)	DK1064935T4 (fr)
EA (1)	EA003751B1 (fr)
ES (1)	ES2307489T5 (fr)
FR (1)	FR2795326B1 (fr)
HU (1)	HU229342B1 (fr)
NO (1)	NO331449B1 (fr)
NZ (1)	NZ505431A (fr)
PL (1)	PL202494B1 (fr)
PT (1)	PT1064935E (fr)
SI (1)	SI1064935T2 (fr)
ZA (1)	ZA200003245B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6776792B1 (en)	1997-04-24	2004-08-17	Advanced Cardiovascular Systems Inc.	Coated endovascular stent
WO2000013667A1 (fr) *	1998-09-08	2000-03-16	Smithkline Beecham Corporation	Comprimes a base de fibres solubles et d'un derive de lipstatine
FR2795326B1 (fr) *	1999-06-28	2001-08-31	Adir	Composition pharmaceutique solide thermoformable a liberation controlee
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6783793B1 (en)	2000-10-26	2004-08-31	Advanced Cardiovascular Systems, Inc.	Selective coating of medical devices
FR2818552B1 (fr) *	2000-12-26	2003-02-07	Servier Lab	Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2818550B1 (fr) *	2000-12-26	2003-02-07	Servier Lab	Composition pharmaceutique solide thermoformable pour la liberation controle de perindopril
US6764505B1 (en)	2001-04-12	2004-07-20	Advanced Cardiovascular Systems, Inc.	Variable surface area stent
US7862495B2 (en)	2001-05-31	2011-01-04	Advanced Cardiovascular Systems, Inc.	Radiation or drug delivery source with activity gradient to minimize edge effects
US7247313B2 (en) *	2001-06-27	2007-07-24	Advanced Cardiovascular Systems, Inc.	Polyacrylates coatings for implantable medical devices
US7175873B1 (en)	2001-06-27	2007-02-13	Advanced Cardiovascular Systems, Inc.	Rate limiting barriers for implantable devices and methods for fabrication thereof
US6565659B1 (en)	2001-06-28	2003-05-20	Advanced Cardiovascular Systems, Inc.	Stent mounting assembly and a method of using the same to coat a stent
US6656216B1 (en)	2001-06-29	2003-12-02	Advanced Cardiovascular Systems, Inc.	Composite stent with regioselective material
GB0117619D0 (en) *	2001-07-19	2001-09-12	Phoqus Ltd	Pharmaceutical dosage form
US20030204180A1 (en) *	2002-04-30	2003-10-30	Kimberly-Clark Worldwide, Inc.	Temperature responsive delivery systems
US7005137B1 (en)	2002-06-21	2006-02-28	Advanceed Cardiovascular Systems, Inc.	Coating for implantable medical devices
US7396539B1 (en)	2002-06-21	2008-07-08	Advanced Cardiovascular Systems, Inc.	Stent coatings with engineered drug release rate
US7622146B2 (en) *	2002-07-18	2009-11-24	Advanced Cardiovascular Systems, Inc.	Rate limiting barriers for implantable devices and methods for fabrication thereof
US7169178B1 (en)	2002-11-12	2007-01-30	Advanced Cardiovascular Systems, Inc.	Stent with drug coating
JP5501553B2 (ja)	2003-04-21	2014-05-21	ユーロ−セルティークエス．エイ．	同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
TWI357815B (en) *	2003-06-27	2012-02-11	Euro Celtique Sa	Multiparticulates
US20060165790A1 (en) *	2003-06-27	2006-07-27	Malcolm Walden	Multiparticulates
ES2336913T3 (es)	2003-08-08	2010-04-19	Biovail Laboratories International Srl	Comprimido de liberacion modificada de hidrocloruro de bupropion.
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US7198675B2 (en)	2003-09-30	2007-04-03	Advanced Cardiovascular Systems	Stent mandrel fixture and method for selectively coating surfaces of a stent
US7563324B1 (en)	2003-12-29	2009-07-21	Advanced Cardiovascular Systems Inc.	System and method for coating an implantable medical device
HRP20090203T1 (en)	2004-03-30	2009-05-31	Euro-Celtique S.A.	Tamper resistant dosage form comprising an adsorbent and an adverse agent
US7553377B1 (en)	2004-04-27	2009-06-30	Advanced Cardiovascular Systems, Inc.	Apparatus and method for electrostatic coating of an abluminal stent surface
RU2273482C2 (ru) *	2004-06-21	2006-04-10	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Фармацевтическая композиция с пролонгированным высвобождением гликлазида
EP1768653A4 (fr) *	2004-06-25	2012-08-01	Univ Texas	Methodes et compositions de traitement du trouble d'hyperactivite avec deficit de l'attention et de l'hyperphenylalanemie
GB2418854B (en)	2004-08-31	2009-12-23	Euro Celtique Sa	Multiparticulates
US7632307B2 (en)	2004-12-16	2009-12-15	Advanced Cardiovascular Systems, Inc.	Abluminal, multilayer coating constructs for drug-delivery stents
US7867547B2 (en)	2005-12-19	2011-01-11	Advanced Cardiovascular Systems, Inc.	Selectively coating luminal surfaces of stents
CA2641351C (fr) *	2006-02-03	2014-05-06	Christian Meier	Compositions pharmaceutiques contenant des melanges de polymeres et d'agents actifs peu solubles dans l'eau
EP2001350A4 (fr) *	2006-03-20	2013-04-17	Teva Womens Health Inc	Anneaux intravaginaux souples et comprimes, leurs procedes de fabrication et d'utilisation et appareil destine a leur fabrication
US8003156B2 (en)	2006-05-04	2011-08-23	Advanced Cardiovascular Systems, Inc.	Rotatable support elements for stents
US8603530B2 (en)	2006-06-14	2013-12-10	Abbott Cardiovascular Systems Inc.	Nanoshell therapy
US8048448B2 (en)	2006-06-15	2011-11-01	Abbott Cardiovascular Systems Inc.	Nanoshells for drug delivery
US8017237B2 (en)	2006-06-23	2011-09-13	Abbott Cardiovascular Systems, Inc.	Nanoshells on polymers
DE102007009242A1 (de) *	2007-02-22	2008-09-18	Evonik Röhm Gmbh	Pellets mit magensaftresistenter Wirkstoff-Matix
JP4642134B2 (ja) *	2007-05-01	2011-03-02	コンサートファーマシューティカルズインコーポレイテッド	ナフチル（エチル）アセトアミド
US8048441B2 (en)	2007-06-25	2011-11-01	Abbott Cardiovascular Systems, Inc.	Nanobead releasing medical devices
US20120065221A1 (en)	2009-02-26	2012-03-15	Theraquest Biosciences, Inc.	Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
CN101481321B (zh) *	2009-02-27	2012-04-18	上海医药工业研究院	阿戈美拉汀卤化氢复合物及其制备方法
WO2012130837A1 (fr)	2011-03-28	2012-10-04	Ratiopharm Gmbh	Agomélatine solide sous une forme non cristalline
EP2550863A1 (fr) *	2011-07-27	2013-01-30	Bayer Intellectual Property GmbH	Particules contenant une matière active à base de polyacrylate
BR112014004753A2 (pt) *	2011-08-30	2017-03-28	Univ Gent	formulação de liberação de multicamadas
WO2014012571A1 (fr)	2012-07-16	2014-01-23	Ratiopharm Gmbh	Complexe d'agomélatine et de cyclodextrine
JO3339B1 (ar) *	2012-09-11	2019-03-13	Shanghai Inst Pharmaceutical Ind	شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
KR101659983B1 (ko)	2012-12-31	2016-09-26	주식회사 삼양바이오팜	용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
ES2645223T3 (es)	2013-06-06	2017-12-04	Zentiva, K.S.	Formulaciones de agomelatina que comprenden agomelatina en forma de co-cristales
EP2810647A1 (fr)	2013-06-06	2014-12-10	Zentiva, a.s.	Formulations pharmaceutiques, comprenant l'agomélatine sous forme d'un co-cristal de l'agomélatine avec un acide organique
CN103724415B (zh) *	2013-12-31	2015-05-27	中山大学	斜带石斑鱼性别调控基因Rspo1及其制备方法和应用
PT109154B (pt) *	2016-02-12	2019-11-05	Univ De Coimbra	Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
FR3070619B1 (fr)	2017-09-01	2024-10-04	Ab7 Innovation	Piece moulee monolithique en matrice multiple pour la diffusion d’actifs et son procede d’obtention
EP3459527B1 (fr)	2017-09-20	2022-11-23	Tillotts Pharma Ag	Procédé de préparation d'une forme posologique solide comprenant des anticorps par granulation par voie humide, extrusion et sphéronisation
US20200289481A1 (en) *	2017-11-02	2020-09-17	Ishihara Sangyo Kaisha, Ltd.	Sustained-release pharmaceutical composition
KR101856911B1 (ko) *	2017-12-13	2018-05-10	동국대학교 산학협력단	펠루비프로펜의 서방성 고체분산체 제제 및 이의 제조방법
CN109985025B (zh) *	2017-12-29	2023-01-13	沈阳药科大学	具有pH触发释药特征的眼部缓释给药系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0544144A1 (fr) *	1991-11-23	1993-06-02	BASF Aktiengesellschaft	Forme pharmaceutique retard solide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5102668A (en) *	1990-10-05	1992-04-07	Kingaform Technology, Inc.	Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
CA2075517C (fr) *	1992-04-01	1997-03-11	John Wick	Piece transdermique incorporant une pellicule de polymeres incorporee a l'aide d'un agent actif
US5965161A (en) *	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
WO1997008950A1 (fr) †	1995-09-07	1997-03-13	Fuisz Technologies, Ltd.	Systeme permettant de rendre biodisponibles des agents bioalterants sensiblement non solubles
DE19539362A1 (de) †	1995-10-23	1997-04-24	Basf Ag	Verfahren zur Herstellung von festen Arzneiformen
DE19728516C2 (de) *	1997-07-04	1999-11-11	Sanol Arznei Schwarz Gmbh	TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol
FR2766088B1 (fr) *	1997-07-17	2001-01-05	Dow Corning Sa	Dispositifs a liberation controlee d'un agent pharmaceutique, leur fabrication par co-extrusion et article intermediaire
FR2795326B1 (fr) *	1999-06-28	2001-08-31	Adir	Composition pharmaceutique solide thermoformable a liberation controlee

1999
- 1999-06-28 FR FR9908210A patent/FR2795326B1/fr not_active Expired - Fee Related
2000
- 2000-06-27 ES ES00401825T patent/ES2307489T5/es not_active Expired - Lifetime
- 2000-06-27 PT PT00401825T patent/PT1064935E/pt unknown
- 2000-06-27 SI SI200031000T patent/SI1064935T2/sl unknown
- 2000-06-27 NZ NZ505431A patent/NZ505431A/xx not_active IP Right Cessation
- 2000-06-27 EP EP00401825A patent/EP1064935B2/fr not_active Expired - Lifetime
- 2000-06-27 NO NO20003349A patent/NO331449B1/no not_active IP Right Cessation
- 2000-06-27 AT AT00401825T patent/ATE395045T1/de active
- 2000-06-27 JP JP2000193043A patent/JP2001031591A/ja active Pending
- 2000-06-27 CA CA002312545A patent/CA2312545C/fr not_active Expired - Fee Related
- 2000-06-27 DE DE60038848T patent/DE60038848D1/de not_active Expired - Lifetime
- 2000-06-27 US US09/604,500 patent/US6319520B1/en not_active Expired - Lifetime
- 2000-06-27 BR BR0002880-0A patent/BR0002880A/pt not_active Application Discontinuation
- 2000-06-27 DK DK00401825.5T patent/DK1064935T4/da active
- 2000-06-27 EA EA200000584A patent/EA003751B1/ru not_active IP Right Cessation
- 2000-06-28 CN CNB001193228A patent/CN1174744C/zh not_active Expired - Fee Related
- 2000-06-28 HU HU0002469A patent/HU229342B1/hu not_active IP Right Cessation
- 2000-06-28 PL PL341042A patent/PL202494B1/pl unknown
- 2000-06-28 ZA ZA200003245A patent/ZA200003245B/xx unknown
- 2000-06-28 KR KR1020000035933A patent/KR100554899B1/ko not_active Expired - Fee Related
- 2000-06-29 AU AU42734/00A patent/AU765885B2/en not_active Ceased
2005
- 2005-12-07 JP JP2005353417A patent/JP2006077033A/ja active Pending
2008
- 2008-06-10 CY CY20081100615T patent/CY1110351T1/el unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0544144A1 (fr) *	1991-11-23	1993-06-02	BASF Aktiengesellschaft	Forme pharmaceutique retard solide

Also Published As

Publication number	Publication date
CY1110351T1 (el)	2015-04-29
EP1064935A1 (fr)	2001-01-03
HU229342B1 (en)	2013-11-28
JP2006077033A (ja)	2006-03-23
AU4273400A (en)	2001-01-04
ATE395045T1 (de)	2008-05-15
HUP0002469A2 (en)	2002-06-29
CN1285188A (zh)	2001-02-28
PT1064935E (pt)	2008-07-03
DK1064935T4 (da)	2011-09-26
EP1064935B2 (fr)	2011-06-08
EP1064935B1 (fr)	2008-05-14
NZ505431A (en)	2002-12-20
NO331449B1 (no)	2012-01-02
KR20010049643A (ko)	2001-06-15
EA200000584A2 (ru)	2000-12-25
BR0002880A (pt)	2001-01-30
CA2312545A1 (fr)	2000-12-28
EA200000584A3 (ru)	2001-04-23
PL341042A1 (en)	2001-01-02
DE60038848D1 (de)	2008-06-26
SI1064935T2 (sl)	2011-12-30
US6319520B1 (en)	2001-11-20
NO20003349L (no)	2000-12-29
CN1174744C (zh)	2004-11-10
JP2001031591A (ja)	2001-02-06
FR2795326B1 (fr)	2001-08-31
ES2307489T5 (es)	2011-11-07
PL202494B1 (pl)	2009-06-30
EA003751B1 (ru)	2003-08-28
CA2312545C (fr)	2006-09-12
NO20003349D0 (no)	2000-06-27
HUP0002469A3 (en)	2008-04-28
HU0002469D0 (en)	2000-08-28
ZA200003245B (en)	2001-01-17
ES2307489T3 (es)	2008-12-01
DK1064935T3 (da)	2008-08-25
AU765885B2 (en)	2003-10-02
HK1033435A1 (en)	2001-08-31
SI1064935T1 (sl)	2008-08-31
FR2795326A1 (fr)	2000-12-29

Publication	Publication Date	Title
KR100554899B1 (ko)	2006-02-24	고체 열성형성 방출 조절 약제 조성물
JP2010100641A (ja)	2010-05-06	イバブラジン制御放出のための熱成形可能な固形医薬組成物
KR100542473B1 (ko)	2006-01-11	페린도프릴의 조절 방출을 위한 열성형가능한 고체 약제조성물
MXPA00006383A (en)	2002-07-25	Solid thermoformable controlled-release pharmaceutical composition
HK1033435B (en)	2005-06-03	Solid thermoformable controlled-release pharmaceutical composition
HK1063739B (en)	2006-01-13	Thermoformable solid pharmaceutical composition for controlled release of perindopril
HK1060514B (en)	2005-09-30	Thermoformable solid pharmaceutical composition for controlled release of ivabradine

Legal Events

Date	Code	Title	Description
2000-06-28	PA0109	Patent application	Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20000628
2001-06-15	PG1501	Laying open of application
2001-10-29	N231	Notification of change of applicant
2001-10-29	PN2301	Change of applicant	Patent event date: 20011029 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D
2002-02-26	A201	Request for examination
2002-02-26	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20020226 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20000628 Comment text: Patent Application
2003-12-29	E902	Notification of reason for refusal
2003-12-29	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20031229 Patent event code: PE09021S01D
2005-01-27	E902	Notification of reason for refusal
2005-01-27	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20050127 Patent event code: PE09021S01D
2005-07-11	E902	Notification of reason for refusal
2005-07-11	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20050711 Patent event code: PE09021S01D
2006-01-03	E701	Decision to grant or registration of patent right
2006-01-03	PE0701	Decision of registration	Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20060103
2006-02-17	GRNT	Written decision to grant
2006-02-17	PR0701	Registration of establishment	Comment text: Registration of Establishment Patent event date: 20060217 Patent event code: PR07011E01D
2006-02-17	PR1002	Payment of registration fee	Payment date: 20060220 End annual number: 3 Start annual number: 1
2006-02-24	PG1601	Publication of registration
2009-01-02	PR1001	Payment of annual fee	Payment date: 20090105 Start annual number: 4 End annual number: 4
2009-12-04	PR1001	Payment of annual fee	Payment date: 20091207 Start annual number: 5 End annual number: 5
2010-12-01	PR1001	Payment of annual fee	Payment date: 20101202 Start annual number: 6 End annual number: 6
2011-12-01	PR1001	Payment of annual fee	Payment date: 20111202 Start annual number: 7 End annual number: 7
2013-01-08	FPAY	Annual fee payment	Payment date: 20130109 Year of fee payment: 8
2013-01-08	PR1001	Payment of annual fee	Payment date: 20130109 Start annual number: 8 End annual number: 8
2013-11-22	FPAY	Annual fee payment	Payment date: 20131125 Year of fee payment: 9
2013-11-22	PR1001	Payment of annual fee	Payment date: 20131125 Start annual number: 9 End annual number: 9
2014-12-19	FPAY	Annual fee payment	Payment date: 20141222 Year of fee payment: 10
2014-12-19	PR1001	Payment of annual fee	Payment date: 20141222 Start annual number: 10 End annual number: 10
2015-12-01	FPAY	Annual fee payment	Payment date: 20151202 Year of fee payment: 11
2015-12-01	PR1001	Payment of annual fee	Payment date: 20151202 Start annual number: 11 End annual number: 11
2016-11-28	FPAY	Annual fee payment	Payment date: 20161129 Year of fee payment: 12
2016-11-28	PR1001	Payment of annual fee	Payment date: 20161129 Start annual number: 12 End annual number: 12
2017-12-05	FPAY	Annual fee payment	Payment date: 20171206 Year of fee payment: 13
2017-12-05	PR1001	Payment of annual fee	Payment date: 20171206 Start annual number: 13 End annual number: 13
2019-02-18	LAPS	Lapse due to unpaid annual fee
2019-02-18	PC1903	Unpaid annual fee	Termination category: Default of registration fee Termination date: 20191130